# JAGX catalysts: Jaguar Health, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/jagx/catalysts

> Jaguar Health, Inc. (JAGX) has no upcoming catalysts in this calendar. The latest recorded is the Jaguar Health, Inc. earnings report, August 19, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Jaguar Health, Inc. |
| Ticker | JAGX (Nasdaq) |
| SEC CIK | 1585608 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/jagx |

## Cash runway

Cash $3.8M as of 2026-06-30; quarterly burn $5.3M; about 2.1 months of runway at that rate (XBRL company facts, accession 0001193125-26-356570).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 12, 2024 | [Mytesi® (crofelemer) FDA approval](https://sec-api.dev/pdufa/crofelemer) | JAGX |  | completed, approved | "As part of our strategy to expand our commercial footprint beyond the FDA approved crofelemer indication for HIV-related supportive care, to include cancer-related supportive care, on April 12, 2024, we entered into an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC ("Venture Life"), an international consumer health company focused on the global self-care market, for Venture Life's 510(k) cleared oral mucositis prescription product, Gelclair, for the US market." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1585608/000119312525282950/jagx-20250930.htm)) |
| Jul 2024 | [Mytesi® (crofelemer) topline data readout](https://sec-api.dev/pdufa/crofelemer) | JAGX |  | completed, missed | "As announced in July of 2024, the top line results from the OnTarget study showed that the trial did not meet its primary endpoint for the prespecified analysis of all tumor types and all targeted therapies." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1585608/000119312526452741/d169732d424b5.htm)) |
| November 13, 2024 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "Jaguar Health Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000095017024125954/jagx-ex99_1.htm)) |
| March 31, 2025 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "SAN FRANCISCO, CA / March 31, 2025 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000095017025047220/jagx-ex99_1.htm)) |
| May 13, 2025 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "Company) today reported its consolidated first-quarter 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000119312525120763/d63848dex991.htm)) |
| April 7, 2026 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "(NASDAQ: JAGX) ("Jaguar" or the "Company") today reported its consolidated fourth-quarter 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/d111491dex991.htm)) |
| May 20, 2026 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "("Jaguar" or the "Company") today reported its consolidated first-quarter 2026 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/d143790dex991.htm)) |
| August 19, 2026 | [Jaguar Health, Inc. earnings report](https://sec-api.dev/companies/jagx/catalysts) | JAGX |  | completed | "/ Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2026 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/d380271dex991.htm)) |

## Drugs

- [Mytesi® (crofelemer)](https://sec-api.dev/pdufa/crofelemer): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/jagx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "JAGX catalysts: Jaguar Health, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/jagx/catalysts

```bibtex
@misc{secapidev_companies_jagx_catalysts_20261116,
  title        = {JAGX catalysts: Jaguar Health, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/jagx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_jagx_catalysts_20261116","title":"JAGX catalysts: Jaguar Health, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/jagx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
